Cetuximab plus FOLFOX for colorectal cancer (EXPLORE): Preliminary efficacy analysis of a randomized phase III trial.

被引：0
|
作者：
Polikoff, J
Mitchell, EP
Badarinath, S
Graham, CD
Jennis, A
Chen, TT
Gustafson, TN
Langer, C
机构：
[1] Kaiser Permanente, San Diego, CA USA
[2] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[3] Florida Oncol Assoc, Jacksonville, FL USA
[4] Charleston Canc Ctr, Charleston, SC USA
[5] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：264S / 264S
页数：1
相关论文
共 50 条
  • [1] Cetuximab plus FOLFOX for colorectal cancer (EXPLORE): Preliminary safety analysis of a randomized phase III trial.
    Badarinath, S
    Mitchell, EP
    Jennis, A
    Graham, CD
    Hansen, VL
    Henderson, CA
    Chen, TT
    Langer, C
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 252S - 252S
  • [2] Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX
    Ciardiello, F.
    Normanno, N.
    Martinelli, E.
    Troiani, T.
    Pisconti, S.
    Cardone, C.
    Nappi, A.
    Bordonaro, A. R.
    Rachiglio, M.
    Lambiase, M.
    Latiano, T. P.
    Modoni, G.
    Cordio, S.
    Giuliani, F.
    Biglietto, M.
    Montesarchio, V.
    Barone, C.
    Tonini, G.
    Cinieri, S.
    Febbraro, A.
    Rizzi, D.
    De Vita, F.
    Orditura, M.
    Colucci, G.
    Maiello, E.
    ANNALS OF ONCOLOGY, 2016, 27 (06) : 1055 - 1061
  • [3] Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of 800 patients in a randomized phase III trial (EPIC).
    Abubakr, Y.
    Eng, C.
    Wong, L.
    Pautret, V.
    Scheithauer, W.
    Maurel, J.
    Kroening, H.
    Lutz, M.
    Zubel, A.
    Sobrero, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 160S - 160S
  • [4] Translational analysis and final efficacy of the AVETUX trial - Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer
    Tintelnot, Joseph
    Ristow, Inka
    Sauer, Markus
    Simnica, Donjete
    Schultheiss, Christoph
    Scholz, Rebekka
    Goekkurt, Eray
    von Wenserski, Lisa
    Willscher, Edith
    Paschold, Lisa
    Lorenzen, Sylvie
    Riera-Knorrenschild, Jorge
    Depenbusch, Reinhard
    Ettrich, Thomas J.
    Doerfel, Steffen
    Al-Batran, Salah-Eddin
    Karthaus, Meinolf
    Pelzer, Uwe
    Hinke, Axel
    Bauer, Marcus
    Massa, Chiara
    Seliger, Barbara
    Wickenhauser, Claudia
    Bokemeyer, Carsten
    Hegewisch-Becker, Susanna
    Binder, Mascha
    Stein, Alexander
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [5] Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of the first 400 patients in a randomized phase III trial (EPIC).
    Sobrero, A
    Scheithauer, W
    Maurel, J
    Mineur, L
    Fehrenbacher, L
    Kisker, O
    Kopit, J
    Langer, C
    Schlichting, M
    Abubakr, Y
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 266S - 266S
  • [6] Efficacy and safety of FOLFOX biweekly cetuximab as first-line therapy for patients with nonresectable metastatic colorectal cancer (CELINE trial): Multicenter phase II trial.
    Kondo, Ken
    Kotake, Masanori
    Doden, Kenji
    Munemoto, Yoshinori
    Kobayashi, Kenji
    Nishimura, Genichi
    Omote, Kazuhiko
    Sakamoto, Junichi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [7] Cetuximab plus folfiri first-line in metastatic colorectal cancer (MCRC): The randomized phase III crystal trial
    Koehne, C.
    Zaluski, J.
    Chung, Rong C.
    Makhson, A.
    D'Haens, G.
    Pinter, T.
    Lim, R.
    Ruff, P.
    Rougier, P.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2007, 18 : VII21 - VII21
  • [8] Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial
    Ocvirk, Janja
    Brodowicz, Thomas
    Wrba, Fritz
    Ciuleanu, Tudor E.
    Kurteva, Galina
    Beslija, Semir
    Koza, Ivan
    Zsuzsanna Papai
    Messinger, Diethelm
    Yilmaz, Ugur
    Zsolt Faluhelyi
    Yalcin, Suayib
    Papamichael, Demetris
    Miklos Wenczl
    Mrsic-Krmpotic, Zrinka
    Shacham-Shmueli, Einat
    Vrbanec, Damir
    Esser, Regina
    Scheithauer, Werner
    Zielinski, Christoph C.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (25) : 3133 - 3143
  • [9] Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial
    Janja Ocvirk
    Thomas Brodowicz
    Fritz Wrba
    Tudor E Ciuleanu
    Galina Kurteva
    Semir Beslija
    Ivan Koza
    Zsuzsanna Pápai
    Diethelm Messinger
    Ugur Yilmaz
    Zsolt Faluhelyi
    Suayib Yalcin
    Demetris Papamichael
    Miklós Wenczl
    Zrinka Mrsic-Krmpotic
    Einat Shacham-Shmueli
    Damir Vrbanec
    Regina Esser
    Werner Scheithauer
    Christoph C Zie-linski
    World Journal of Gastroenterology, 2010, 16 (25) : 3133 - 3143
  • [10] Phase II trial of imatinib, bevacizumab and cetuximab plus modified FOLFOX-6 in advanced untreated colorectal cancer
    Sobrero, A. F.
    Bennicelli, E.
    Pessino, A.
    Guglielmi, A.
    Mammoliti, S.
    Caprioni, F.
    Fornarini, G.
    Comandini, D.
    Sciallero, S.
    Ansaldi, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345